Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

NCT ID: NCT04239859

Last Updated: 2022-11-25

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-31
• Study Completion Date: 2027-12-31

Brief Summary

Psoriasis (PsO) is a systemic immune disease that affect 2-4% of the population worldwide. PsO causes tremendous burden in terms of quality of life, psychological impact, disability and work productivity of affected individuals. PsO is associated with an increased risk of cardiovascular morbidities and mortality in the long term. Up to 30% of PsO patients develop psoriatic arthritis (PsA) over time causing joint deformities and further disabilities. Majority of patients with PsA developed PsO first, and arthritis develop 5-10 years after. PsA and PsO are increasingly recognized as two entities under the umbrella of psoriatic diseases.

Advances in biological treatments have greatly improved the prognosis of patients with PsO. Remarkable efficacies have been demonstrated for patients with moderate to severe PsO in randomized controlled trials (RCTs). However, the high cost of biological treatment is one of the major barriers to its prescription and many patients may have limited access to these treatments.

The best treatment strategy for PsO that takes into account efficacy and cost effectiveness is unknown. For instance, whether some PsO patients can stop biological treatment and be treated with non-biologic medications upon relapse, which may enhance cost effectiveness of treatment. Preliminary studies have shown that some PsO patients were able to maintain good control of disease without medications after biologics withdrawal. The patho-immunological mechanisms behind long term remission after drug withdrawal is poorly understood. Better understanding of these mechanisms in maintaining remission and relapses will advance the development of biomarkers that eventually guide development of best treatment strategies for PsO.

Secukinumab targets interleukin (IL)-17a and is highly efficacious in the treatment of plague PsO with a favorable safety profile. Some patients may have the response maintained after withdrawal of secukinumab. With the proven efficacies, sustainability after withdrawal and safety profile, secukinumab could be a choice of initial treatment for patients with moderate to severe PsO. Secukinumab has been recommended as first line treatment for selected patients with moderate to severe PsO by the American Academy of Dermatology and the European S3 guidelines. However, the use of biologics as first line is limited by cost issue. Overall, real-life data on biologic treatment for moderate to severe PsO is scanty.

Detailed Description

First, the investigators hypothesize that a proportion of participants with moderate to severe PsO may sustain good outcomes when a short course of secukinumab is withdrawn.

Second, the investigators hypothesize that they can identify the perturbations in the architecture of the immunome which are pathogenic, and to discriminate such perturbations based on treatment and clinical responses, thus distilling therapeutics and diagnostics signatures.

Therefore, the objectives of this study are as follow:

Specific aim 1: To describe the clinical course, sustained good outcomes, relapse rate, time to relapse and quality of life in PsO participants who stopped a 6-month short course treatment of secukinumab, till the end of 2-years.

Specific aim 2: To identify the genomic and immunomics signatures in skin biopsies and blood in PsO participants who has good outcomes (PASI 75) at 6 months, comparing treatment vs pragmatic control.

Specific aim 3: To identify the genomic and immunomics signatures in skin biopsies and blood in PsO participants who sustained good outcomes at 1 year after stopping secukinumab, compared to those relapsed.

Conditions

Plaque Psoriasis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Secukinumab

Participants will be offered secukinumab as first-line systemic treatment for moderate to severe PsO. The indication for secukinumab will be equivalent to current registered indications. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months.

secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care.

Group Type: EXPERIMENTAL

secukinumab

Intervention Type: BIOLOGICAL

Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.

Standard Care

The management of PsO in the control arm will be the same as that in the standard care.

The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A.

Group Type: ACTIVE_COMPARATOR

Methotrexate

Intervention Type: DRUG

Oral tablet up to 15mg per week

Cyclosporin A

Intervention Type: DRUG

Oral capsule up to 200mg per day

Acitretin

Intervention Type: DRUG

Oral capsule up to 25mg per day

Interventions

secukinumab

Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.

Intervention Type: BIOLOGICAL

Methotrexate

Oral tablet up to 15mg per week

Intervention Type: DRUG

Cyclosporin A

Oral capsule up to 200mg per day

Intervention Type: DRUG

Acitretin

Oral capsule up to 25mg per day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adults (>21-year-old).
• Diagnosed by dermatologist as plague-type PsO.
• Having moderate to severe plague-type PsO as defined by the following:
• Psoriasis Area and Severity Index (PASI) ≥12/72,
• And, investigator Global Assessment Score (IGA) ≥3,
• And, PsO involving body surface area involvement (BSA) ≥10%
• And Candidate for phototherapy and/or systemic therapy
• Topical corticosteroid up to moderate potencies are allowed
• Able to provide informed consent.

Exclusion Criteria

• Forms of PsO other than plaque-type.
• Evidence of skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluation of the effect of the investigational product on PsO.
• Evidence of active tuberculosis or other active infections (like Hepatitis C/B), malignancy; active or known use of other immunosuppressive drugs (eg. AIDS, rheumatoid arthritis, organ rejection etc) at the screening visit.
• Previous exposure to any systemic immunosuppressants (eg. methotrexate) or phototherapy
• History or current signs of a severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
• Having current or history of malignancy, except non-melanoma skin cancer, within the previous 5 years that have been adequately treated.
• History of inflammatory bowel disease.
• Pregnancy or lactating mothers.
• As treatment regimen is different, participants with evidence of PsA will be excl

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Translational Immunology Institute

UNKNOWN

Sponsor Role: collaborator

Singapore General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ying Ying Leung, MD

Role: PRINCIPAL_INVESTIGATOR

Singapore General Hospital

Locations

Singapore General Hospital

Outram Park, , Singapore

Countries

Singapore

Central Contacts

Ying Ying Leung, MD

Role: CONTACT

katy.leung.y.y@singhealth.com.sg

+65 63265276

Cynthia Ong, Bachelor

Role: CONTACT

cynthia.ong.s.q@singhealth.com.sg

+65 65762609

Facility Contacts

Ying Ying A/Prof Leung

Role: primary

katy.leung.y.y@singhealth.com.sg

+65 63265276

Other Identifiers

PsO1

Identifier Type: -

Identifier Source: org_study_id